Georg Schett co-founds biotech focused on antibody therapies
Get the Health newsletter
Daily health & science — research, biotech, public health, the studies worth knowing. Free.
- Georg Schett is co-founding a biotech company for the first time, after years of serving as a scientific adviser on a half-dozen startup advisory boards
- Schett has spent the last five years establishing himself as a pioneer in autoimmune disease treatment, with research showing CAR-T therapy could reset patients' immune systems
- The new biotech company is focused on antibody therapies and has no immediate plans to work in CAR-T, despite Schett's expertise in that modality
Why it matters: Schett's move from advising half a dozen startups to co-founding his own signals a deeper personal stake in commercial autoimmune research, and the deliberate choice to pursue antibodies over CAR-T reframes the company around a more conventional drug-development path than his published breakthroughs would suggest.
Ask SkimNews
